Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Ex-Tesco chief Sir Dave Lewis to head up £45bn GSK consumer spin-off

GSK told investors that Sir Dave, who left the UK’s largest grocer in September last year, will take up the role from January 1.

Henry Saker-Clark
Monday 20 December 2021 07:58 GMT
Ex-Tesco chief Sir Dave Lewis will chair GSK’s new consumer healthcare business (Joe Giddens/PA)
Ex-Tesco chief Sir Dave Lewis will chair GSK’s new consumer healthcare business (Joe Giddens/PA) (PA Archive)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Pharmaceutical giant GlaxoSmithKline (GSK) has hired former Tesco boss Sir Dave Lewis to chair the consumer healthcare business it plans to spin off next year.

GSK told investors on Monday morning that Sir Dave, who left the UK’s largest grocer in September last year, will take up the role from January 1.

The group’s consumer healthcare business – whose brands include Sensodyne toothpaste and Panadol paid relief – is set to demerge from the wide group in “mid 2022” and list separately on the London Stock Exchange.

Analysts have predicted that the spin-off, which is a joint venture with Pfizer and secured more than £10 billion in sales last year, will be worth around £45 billion.

Sir Dave was credited with driving a major turnaround at Tesco following its accounting scandal, having moved from rival consumer group Unilever.

Since leaving Tesco, he has joined the board of snack and drinks firm PepsiCo and become chairman of wildlife charity WWF-UK.

In October, the industry veteran was also appointed by Prime Minister Boris Johnson to advise the Government on how to tackle the supply chain crisis which had resulted in staff and labour shortages across the UK.

It comes after confirmation earlier this year that the current boss of the consumer healthcare division, Brian McNamara, will become chief executive of the spin-off.

Sir Dave said: “GSK Consumer Healthcare is a world-class business with significant prospects and a high-quality leadership team.

“I am looking forward to being part of its exciting future as an independent company and the very positive impact it can have on people’s health all over the world.”

GSK chairman Sir Jonathan Symonds said: “I am delighted to welcome Dave as chair-designate of the new consumer healthcare company.

“He brings outstanding global consumer and retail sector experience that will be of valuable support to Brian and the management team as they deliver the full potential of this new world-leading consumer healthcare company.”

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in